Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
Startups in the ambient documentation space are moving beyond simple scribing to tools that can handle tasks like intake, coding and care coordination, according to Heidi Health CEO Tom Kelly. Standing out in this crowded market is a challenge, and companies' success will hinge on creating products clinicians actually want to use, he added.
Eli Lilly is paying $75 million up front for global rights to AAV-AIPL1, a gene therapy on track for U.S. and European regulatory submissions in the rare, inherited eye disorder Leber congenital amaurosis 4, or LCA4. The deal brings to Lilly another late-stage gene therapy for the eyes following the pharma giant's October acquisition of Adverum Biotechnologies and its lead program for wet AMD.
The future of healthcare isn't about one company "owning it all." It's about building the kind of ecosystem Apple unlocked with the iPhone and its App Store — one that empowers and changes the game for everyone.
Authority built on information control cannot survive in the age of AI and instant access. But authority built on wisdom, judgment, empathy, and genuine partnership? That's eternal. And it's exactly what patients have been asking for all along.
There is no question that EHRs have created major administrative burdens, noted Nikhil Buduma, CEO of Ambience Healthcare.
These systems are causing clinicians to spend most of their time on documentation and billing work instead of connecting with patients. Buduma said Ambience aims to solve this by integrating AI directly into EHR workflows to automate tasks before, during and after the visit.
The goal is to remove non-clinical work so clinicians can focus on the patient in front of them and restore joy in practicing medicine.
How many companies will be left standing once consolidation hits the AI in healthcare sector? Which pharma companies are working with the Trump administration to lower costs?
No comments